Navigation Links
Interferon-beta aids balance and movement in mice with spinocerebellar ataxia 7
Date:6/9/2013

Paris, France: The group of genetic conditions known as spinocerebellar ataxias currently have no treatment or cure and are always fatal, in the case of affected children at an early age. Symptoms include a progressive lack of co-ordination of gait, and poor co-ordination of hands, speech and eye movements, due to a failure of co-ordination of muscle movements. Now researchers from France and the US have found a new way of controlling the symptoms and significantly improving the physical condition of animal models of the disease, the annual conference of the European Society of Human Genetics will hear today (Monday June 10).

Dr. Annie Sittler, from the Centre National de la Recherche Scientifique (CNRS), working in the team of Professor Alexis Brice at the research centre Brain and Spinal Cord Institute (CR-ICM), Paris, France described the team's work in the field of polyglutamine disease, a group of neurodegenerative conditions involving abnormal protein conformation. "Accumulation of a polyglutamine-containing protein known as mutant ataxin -7 is responsible for neurotoxicity, neuronal dysfunction, and eventually neuronal death", she explains. "We had previously shown in cells that mutant ataxin-7 was degraded in nuclear bodies, structures found in the nucleus of cells, by a protein known as promyeloctyic leukaemia protein or PML, and that interferon-beta could help with this process and protect against disease."

The researchers used a mouse model of a particular form of spinocerebellar ataxia known as SCA7. The genetically-modified 'knock-in' mice develop the severe type of the disease, similar to the infantile human version, and have a very short lifespan of around 14 weeks. They were injected with mouse interferon-beta three times a week, starting at five weeks of age, just before their first symptoms of disease were due to appear. Investigation of their brains post-mortem showed that the mice who had received the interferon-beta, as opposed to those in the control group, had a reduced load of mutant ataxin-7.

On the physical level, substantial improvements in the interferon-beta treated mice were noticed. "At twelve weeks of age the physical performance of the mice that received the active substance was significantly improved compared to the control group. We gave them a locotronic test, where they have to cross a kind of ladder. This test is used to check motor co-ordination when walking. We also put them through a beam-walking test, which enables us to measure their balance and limb co-ordination. The treated mice did much better in both of these tests", Dr. Sittler will say.

Further proof of the positive effects of interferon-beta came from analysis of the PML nuclear bodies, involved in many cellular processes such as transcriptional regulation and apoptosis. A subset of these nuclear bodies is responsible for regulating the degradation of accumulated misfolded proteins in the cell nucleus. The treated mice had more, and very much larger, PML bodies, and they were present in the Purkinje cells, responsible for motor co-ordination emanating from the cerebellum The researchers further found that these PML bodies were clastosomes, the specialised nuclear bodies involved in the degradation of mutant ataxin-7 and other polyglutamine-containing proteins. "This, together with the physical improvements we saw in the interferon-beta treated mice, was the proof we needed that our findings in the cell could be successfully transferred to living animals", says Dr. Sittler.

"Now that we have found that interferon-beta can slow progression of disease in SCA7 mice, we believe that, after confirmation in another mouse model, it would be merited to test its effects on humans in a clinical trial,", she will say. "Such trials are difficult in rare diseases, since a special design is needed to test a hypothesis on a small number of patients. However, there are a number of other polyglutamine diseases, for example Huntington's, where patient numbers are larger, and the effects of the condition just as devastating. We hope that our results will encourage others to collaborate with us in order that we may be able to pursue our research to the benefit of all those afflicted with spinocerebellar disorders."


'/>"/>

Contact: Mary Rice
mary.rice@riceconseil.eu
European Society of Human Genetics
Source:Eurekalert

Related biology news :

1. A war without end -- with Earths carbon cycle held in the balance
2. Indonesian fishing communities find balance between biodiversity and development
3. Shifting the balance between good fat and bad fat
4. New menhaden study will help identify balance between fishing and preserving Bay forage fish
5. Decoding the secrets of balance
6. Researchers find mechanism that gives plants balance
7. Increasing water scarcity in Californias Bay-Delta will necessitate trade-offs; hard decisions needed to balance various environmental risks
8. Scientists join forces to bring plant movement to light
9. Outside a vacuum: Model predicts movement of charged particles in complex media
10. 3dMD Transitions Anatomical Research from 3D-Static to 4D-Movement Surface Imaging
11. Research identifies mechanism responsible for eye movement disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... compared with fourth quarter of 2014. Gross margin was 46% ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... , --> --> January ... (233.6), up 1,142% compared with 2014. Gross margin was 43% ...
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert Technologies, ... continues today to pursue the highest level of accuracy and quality with the ... Refractometer and the AR5 Refractometer. Accurate, reliable and tough enough for the ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... Ky. , Feb. 10, 2016 NX ... utilizing its proprietary NeXosome® technology for early warning ... of its most recent study by Dr. ... at the Society for Maternal Fetal Medicine,s (SMFM) annual ... GA, February 1-6 th , 2016.  The presentation reported ...
(Date:2/10/2016)... 10, 2016  IsoRay, Inc. (NYSE MKT: ISR), a ... medical radioisotope applications for the treatment of prostate, brain, ... its financial results for the second quarter and six ... --> --> ... fiscal 2016, which ended December 31, 2015, a 12% ...
Breaking Biology Technology: